Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
90
resultados
Última actualización
29/10/2026 [07:30:00]
Resultados 75 a 90 de 90
Resumen de: UA164235U
Method for preparing 4-(2-(difluoromethoxy)phenyl)-5-methylthiazol-2-amine: , which exhibits predicted activity against the SARS-CoV-2 virus, according to which a mixture of equimolar amounts of 2-bromo-1-(2-(difluoromethoxy)phenyl)propan-1-one and thiourea is boiled for three hours in propan-2-ol, cooled, filtered and suspended in 50 ml of saturated NaHCO3 solution, stirred for 5 hours, filtered, washed with water, crystallized from propan-2-ol.
Resumen de: US20260256871A1
0000 The application is directed to methods for treatment or prevention of SARS-CoV-2 infection in a subject in need thereof, the composition comprising an organic acid (e.g., ascorbic acid), glutathione, a glutathione derivative, a glutathione conjugate, a pharmaceutically acceptable salt thereof, and methods of using the same.
Resumen de: US20260256905A1
0000 Waning immunity induced by first-generation Spike-alone-based COVID-19 has failed to prevent immune escape by many variants of concern (VOCs) that emerged from 2020 to 2024, resulting in a prolonged COVID-19 pandemic. Thus, a next-generation Coronavirus (CoV) vaccine incorporating highly conserved non-Spike SARS-CoV-2 antigens is described herein. Conserved non-Spike T cell antigens in combination with a Spike antigen encapsulated in lipid nanoparticles: (i) Induced high frequencies of lung-resident antigen-specific CXCR5+CD4+ T follicular helper cells, GzmB+CD4+ and GzmB+CD8+ cytotoxic T cells, and CD69+IFN-γ+TNFα+CD4+ and CD69+IFN-γ+TNFα+CD8+ effector T cells; and (ii) Reduced viral load and COVID-19-like symptoms caused by various VOCs. The combined antigen/LNP-based pan-CoV vaccine could be rapidly adapted for clinical use to confer broader cross-protective immunity against emerging highly mutated and pathogenic VOCs.
Resumen de: MX2025002403A
The invention relates to a method for the green synthesis of carbon quantum dots with bactericidal and virucidal properties, formed from a mixture of: a plant extract as a carbon source with antioxidant and polyphenol-rich capacity (ratio of between 20-30%); a fruit extract as a source of oxygen rich in vitamin C and antioxidants (with a proportion of between 10-20%); and a plant extract as a source of nitrogen with a high antioxidant content (with a proportion of between 0.5-3%) in aqueous medium (50-60%) resulting in the production of a suspension CQDs having an average diameter of 5-15 nm, hemispherical morphology and with fluorescence emission capacity in blue. The invention includes the reaction process from the use of a pressure heating system and a series of filtrates, resulting in an aqueous suspension of CQDs doped with nitrogen and oxygen species in concentrations ranging from 0.1-30 mg/mL. As a result of the reaction, it is demonstrated that CQDs present the complete growth inhibition of S aureus and P aeruginosa, demonstrating their broad bactericidal capacity against common pathogens in hospital environments. Simultaneously, it is demonstrated that CQDs obtained by environmentally-friendly processes exhibit high virucidal capacity upon contact with viruses such as herpes simplex (HSV1) and SARS-CoV2 upon contact within Vero cells employed as huesped, leading to respiratory diseases. This results in the synthesis of antimicrobial carbon nanomaterials from natural
Resumen de: MX2026006843A
The present disclosure relates to methods of diseases and/or conditions associated with Covid-19 infection, including long COVID, comprising administration of a COX-2 inhibitor, an antiviral compound, and one or more additional active ingredients, such as a combination of nirmatrelvir and ritonavir, molnupiravir, BCG vaccine, or ivermectin.
Resumen de: KR20260132653A
본 발명은 SARS-COV-2 바이러스 감염 질환의 중증도 예측용 바이오마커에 관한 것으로, SARS-COV-2 바이러스 감염 질환의 중증 환자 및 경증 환자에 대한 임상 데이터를 활용하여 cis-eQTM 분석을 통해 32종의 DNA 메틸화 마커 및 상기 DNA 메틸화 마커에 의해 차별적으로 발현되는 18종의 유전자 또는 단백질 마커를 제공한다.
Resumen de: US20260259196A1
Disclosed are methods for detecting if a biological sample (e.g., saliva, serum, blood, plasma) from a subject that has been administered a an immunogenic composition directed to a seasonal influenza virus and an immunogenic composition directed to a SARS-COV-2 virus contains antibodies that inhibit influenza virus hemagglutinin (HA) glycoprotein hemagglutination activity, antibodies that neutralize SARS-COV-2 virus, antibodies that bind SARS-COV-2 spike protein, and/or antibodies that neutralize seasonal influenza virus. The methods include assaying a biological sample, where the biological sample is from a subject that has been administered an immunogenic composition directed to a seasonal influenza virus and an immunogenic composition directed to a SARS-COV-2 virus, and is not significantly affected by interference of analyte detection between the methods.
Resumen de: US20260259197A1
The present invention relates to a COVID-19 infection model using alveolar organoids. Respiratory virus-infected alveolar organoids produced according to the present invention are expected to be usefully used in preclinical or clinical drug screening and the like for the development of therapeutic agents for SARS-CoV-2 infection.
Resumen de: US20260259220A1
0000 Disclosed are methods for detecting if a biological sample (e.g., saliva, serum, blood, plasma) contains IgA antibodies against SARS-CoV-2 S glycoproteins. The method includes contacting a biological sample with a SARS-CoV-2 S glycoprotein-coated surface, contacting the surface with a secondary antibody, and detecting the secondary antibody, where if a secondary antibody is detected, the sample contains IgA antibodies against the SARS-CoV-2 S glycoprotein. Assay substrates and kits for performing such methods are also disclosed.
Resumen de: CN122641466A
The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
Resumen de: MX438089B
The subject invention provides a method for treating, reducing the incidence, suppressing or inhibiting a viral infection, disease, disorder or symptoms thereof in a subject in need thereof comprising administering to the subject a selective SIR agonist. In another aspect, the viral disease is COVID-19, and the selective SIR agonist is pridopidine or pharmaceutically acceptable salt thereof.
Resumen de: WO2026182475A1
The present invention relates to a recombinant adenovirus comprising a SARS-CoV-2-derived receptor-binding domain and an antibody Fc region, and a use thereof, and provides: a polynucleotide comprising a SARS-CoV-2 spike-derived receptor-binding domain and an antibody Fc region; a recombinant adenovirus comprising the polynucleotide; and a vaccine composition for preventing SARS-COV-2 infection, comprising the recombinant adenovirus as an active ingredient.
Resumen de: EP4799624A2
Methods and compositions for treating RNA viral infections, including behavior symptoms of the RNA viral infections, are disclosed herein. Also disclosed are methods and compositions for reducing the progression of clinical complications associated with RNA viral infections. The methods, for example, can include administering pharmaceutical compositions comprising Pipendoxifene or analogues thereof (e.g., a compound of Formula (I), Formula (II), or Formula (III)) to a patient in need. One or more additional therapeutic agents can also be administered to the patient in the disclosed methods.
Resumen de: MA70856A1
Cette invention est relative à de nouveaux composés à base de lacide éthacrynique couplé avec des acides aminés modifiés comme lillustre la formule (I). Ces composés sont conçus pour le traitement du SARS-CoV-2, des pathologies liées à la COVID-19, ainsi que des maladies associées aux -coronavirus. Cette invention porte également sur leur application in vitro pour étudier l'inhibition de la réplication du SARS CoV2. De plus, cette invention inclut des compositions pharmaceutiques comprenant, comme principe actif, au moins un composé de la formule (I).
Nº publicación: SI4514842T1 31/08/2026
Solicitante:
ASTRAZENECA UK LTD [GB]
AstraZeneca UK Limited
Resumen de: WO2023209177A1
The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to the spike protein of SARS-CoV-2 and methods of making and using the same. The antibodies can be used, for example, in prophylaxis, post-exposure prophylaxis, or treatment of SARS-CoV-2 infection. The antibodies can also be used to detect SARS-CoV-2, e.g., an infection in subject.
BOPI
Sede Electrónica
